DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares traded.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the company. HC Wainwright assumed coverage on DICE Therapeutics in a research report on Monday, July 18th. They issued a “buy” rating and a $40.00 target price for the company. Cantor Fitzgerald began coverage on DICE Therapeutics in a report on Wednesday, September 14th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, Stifel Nicolaus began coverage on DICE Therapeutics in a report on Tuesday, September 6th. They set a “buy” rating and a $37.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.33.
DICE Therapeutics Price Performance
The company has a fifty day simple moving average of $18.47 and a two-hundred day simple moving average of $17.73. The company has a market capitalization of $701.17 million and a P/E ratio of -4.80.
Hedge Funds Weigh In On DICE Therapeutics
DICE Therapeutics Company Profile
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.